Clinical Trials & Medical Discoveries

Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting

by

— Breadth of pipeline featured in multiple early clinical data presentations, reflecting diversity of fundamental growth drivers across development programs — CAMBRIDGE, Mass., June 3, 2023 /PRNewswire/ — Blueprint Medicines Corporation (Nasdaq: BPMC) today announced clinical data for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual … Read more

Study Helps Explain What Drives Psoriasis Severity and Offers Clues as to How Disease May Spread to Other Body Parts

by

NEW YORK, June 2, 2023 /PRNewswire/ — Beneath and beyond the reddish, flaky lesions that form in the skin of those with psoriasis, mild and severe forms of the disease can be told apart by the activity of key cells and signaling pathways, a new study shows. Led by researchers at NYU Grossman School of … Read more

Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups

by

Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of disease stage, menopausal or nodal status1 Results were also consistent across all secondary endpoints, including distant disease-free survival and recurrence-free survival, with a trend for improved overall … Read more

Redwood Pharma presents positive results from a clinical study with RP501 against dry eye

by

STOCKHOLM, May 31, 2023 /PRNewswire/ — Redwood Pharma AB (publ) announces positive results from the company’s clinical study with RP501, a medical technology self-care product being developed for the treatment of dry eye. The results show that RP501 is safe and well-tolerated and that the product produces statistically significant positive results on several subjective efficacy measures, … Read more

Advances of Qilu Pharmaceutical’s QL1706 in Clinical Research Presented at ASCO Annual Meeting

by

JINAN, China, May 31, 2023 /PRNewswire/ — The American Society of Clinical Oncology (ASCO) recently announced the selected abstracts for the prestigious ASCO 2023 Annual Meeting. Four clinical research abstracts on QL1706 (iparomlimab/tuvonralimab), an innovative bifunctional antibody for immunotherapy, were accepted in the Poster Session. Two of the posters focus on the latest clinical research progress of Qilu … Read more

VESTECK CONTINUES TO HELP PATIENTS AROUND THE WORLD

by

WEST CHESTER, Pa., May 31, 2023 /PRNewswire/ — VESTECK, Inc. is excited to announce the successful completion of 7 Endovascular Aortic Repair (EVAR) clinical cases with the “SUTURE-TIGHT”™ device. Professor Dainis Krievins and Dr. Bao Bui, performed the 2 most recent EVAR procedures in Riga, Latvia, suturing EVAR grafts to the aorta with the “SUTURE-TIGHT”™ … Read more

Hoag Hospital clinical study demonstrates Luna reduces post-surgical rehab costs by 52%

by

ROCKLIN, Calif., May 31, 2023 /PRNewswire/ — In a groundbreaking study, Hoag Hospital, a leading not-for-profit regional health care delivery network in Orange County, California, presented the results of a two-year analysis at the 2023 American Association of Orthopedic Executives (AAOE) conference. The study demonstrated that the Luna in-home outpatient physical therapy care model reduces costs … Read more

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand USA – English USA – English

by

MUMBAI, India and SIENA, Italy, May 30, 2023 /PRNewswire/ — Sun Pharmaceutical Industries Limited (Reuters: SUN.BO), (Bloomberg: SUNP IN), (NSE: SUNPHARMA), (BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Philogen S.p.A (BIT: PHIL) today announced that they have entered into a licensing agreement for commercializing Philogen’s specialty product, Nidlegy™ (Daromun) in … Read more

Se otorga la cuarta aprobación IDE de Concept Medical para el balón recubierto de sirolimus MagicTouch para el tratamiento de la enfermedad de la arteria femoral superficial (SFA) USA – español USA – English USA – English USA – Deutsch

by

TAMPA, Fla., 30 de mayo de 2023 /PRNewswire/ — El 24 de mayo de 2023, la FDA de EE.UU. otorgó una exención de dispositivo de investigación (IDE) para el balón recubierto de sirolimus (SCB) MagicTouch PTA de Concept Medical Inc para el tratamiento de las arterias femorales superficiales (SFA). Esto marca la cuarta aprobación de IDE para el balón … Read more

Concept Medical’s fourth IDE approval for the MagicTouch Sirolimus Coated Balloon is granted for the treatment of Superficial Femoral Artery Disease (SFA)

by

TAMPA, Fla., May 29, 2023 /PRNewswire/ — The US FDA, on the 24th of May 2023, granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc’s Sirolimus Coated Balloon (SCB) MagicTouch  PTA for the treatment of Superficial Femoral Arteries (SFA). This marks the fourth IDE approval for the Company’s Sirolimus coated balloon. The Company has … Read more